Foravirumab is a monoclonal antibody for the prophylaxis of rabies.[1] It is under development by Sanofi/Crucell.[2]
This antiinfective drug article is a stub. You can help Wikipedia by expanding it.
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.